Research progress on the intrinsic link between the occurrence and progression of malignant tumors, chronic kidney disease and drug safety

There is a close intrinsic link between the occurrence, development, and medication use of malignant tumors and chronic kidney disease (CKD). Firstly, CKD provides conditions for the occurrence and progression of malignant tumors, such as the accumulation of uremic toxins, inflammatory responses, immune dysfunction, and metabolic disorders. Simultaneously, malignant tumors can damage the kidneys through paraneoplastic effect, direct tumor invasion, or compression. In addition, the treatment of malignant tumors can also trigger or worsen CKD. Therefore, improving early cancer screening for CKD patients and exploring the safety of medications used in CKD patients with concurrent cancer are of significant clinical importance. Based on this, this article reviews recent research on the interaction between CKD and malignant tumors and the safety of medications used, aiming to provide important theoretical basis for improving the diagnosis and treatment of CKD with concurrent cancer and improving the prognosis of these patients.